Abstract
While most of the pharmacological therapies for melanoma utilize the apoptotic machinery of the cells, the available therapeutic options are limited due to the ability of melanoma cells to resist programmed cell death. Human melanoma cell lines A-375 and M186 are sensitive to ceramide- and Fas-induced cell death, while Mel-2a and M221 are resistant. We have now found that Mel-2a and M221 cells have a significantly higher ceramide/sphingosine-1-phosphate (S1P) ratio than A-375 and M186 cells. As sphingosine kinase (SphK) type 1 plays a critical role in determining the dynamic balance between the proapoptotic sphingolipid metabolite ceramide and the prosurvival S1P, we examined its role in apoptosis of melanoma cells. Increasing SphK1 expression reduced the sensitivity of A-375 melanoma cells to Fas- and ceramide-mediated apoptosis. Conversely, downregulation of SphK1 with small interfering RNA decreased the resistance of Mel-2a cells to apoptosis. Importantly, overexpression of the prosurvival protein Bcl-2 in A-375 cells markedly stimulated SphK1 expression and activity, while downregulation of Bcl-2 reduced SphK1 expression. This link between Bcl-2 and SphK1 might be an additional clue to chemotherapy resistance of malignant melanoma.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- IAP:
-
inhibitor of apoptosis protein
- S1P:
-
sphingosine-1-phosphate
- SphK:
-
sphingosine kinase
- ERK:
-
extracellular regulated kinase
- PDGF:
-
platelet-derived growth factor
- VEGF:
-
vascular endothelial growth factor
- NGF:
-
nerve growth factor
- bFGF:
-
basic fibroblast growth factor
- Apaf-1:
-
apoptosis-activating factor-1
References
Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z and Kolesnick R . (1995). Cell, 82, 405–414.
Bours V, Bentires-Alj M, Hellin AC, Viatour P, Robe P, Delhalle S, Benoit V and Merville MP . (2000). Biochem. Pharmacol., 60, 1085–1089.
Bruggen J, Fogh J and Sorg C . (1981). J. Cancer Res. Clin. Oncol., 102, 141–152.
Buehrer BM, Bardes ES and Bell RM . (1996). Biochim. Biophys. Acta, 1303, 233–242.
Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, Gutkind S and Spiegel S . (1996). Nature, 381, 800–803.
Eberle J, Fecker LF, Bittner JU, Orfanos CE and Geilen CC . (2002). Br. J. Cancer, 86, 1957–1962.
Edsall L, Vann L, Milstien S and Spiegel S . (2000). Methods Enzymol., 312, 9–16.
Edsall LC and Spiegel S . (1999). Anal. Biochem., 272, 80–86.
Edsall LC, Pirianov GG and Spiegel S . (1997). J. Neurosci., 17, 6952–6960.
Endo K, Igarashi Y, Nisar M, Zhou QH and Hakomori S . (1991). Cancer Res., 51, 1613–1618.
French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL, Yun JK and Smith CD . (2003). Cancer Res., 63, 5962–5969.
Geilen CC, Barz S and Bektas M . (2001). Skin Pharmacol. Appl. Skin Physiol., 14, 261–271.
Gewirtz DA . (1999). Biochem. Pharmacol., 57, 727–741.
Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H and Parks WP . (1973). J. Natl. Cancer Inst., 51, 1417–1423.
Govindarajan B, Bai X, Cohen C, Zhong H, Kilroy S, Louis G, Moses M and Arbiser JL . (2003). J. Biol. Chem., 278, 9790–9795.
Grassme H, Cremesti A, Kolesnick R and Gulbins E . (2003). Oncogene, 22, 5457–5470.
Grossman D, McNiff JM, Li F and Altieri DC . (1999). J. Invest. Dermatol., 113, 1076–1081.
Iervolino A, Trisciuoglio D, Ribatti D, Candiloro A, Biroccio A, Zupi G and Del Bufalo D . (2002). FASEB J., 16, 1453–1455.
Jayadev S and Hannun YA . (1996). J. Lipid Mediat. Cell Signal., 14, 295–301.
Jendiroba DB, Klostergaard J, Keyhani A, Pagliaro L and Freireich EJ . (2002). Leukemia Res., 26, 301–310.
Johnson KR, Becker KP, Facchinetti MM, Hannun YA and Obeid LM . (2002). J. Biol. Chem., 277, 35257–35262.
Kortylewski M, Heinrich PC, Kauffmann ME, Bohm M, MacKiewicz A and Behrmann I . (2001). Biochem. J., 357, 297–303.
Liu H, Sugiura M, Nava VE, Edsall LC, Kono K, Poulton S, Milstien S, Kohama T and Spiegel S . (2000). J. Biol. Chem., 275, 19513–19520.
Liu YY, Han TY, Giuliano AE, Ichikawa S, Hirabayashi Y and Cabot MC . (1999). Exp. Cell Res., 252, 464–470.
Lockshin A, Giovanella BC, De Ipolyi PD, Williams Jr LJ, Mendoza JT, Yim SO and Stehlin Jr JS . (1985). Cancer Res., 45, 345–350.
Ogretmen B and Hannun YA . (2001). Drug Resist. Update, 4, 368–377.
Ogretmen B, Pettus BJ, Rossi MJ, Wood R, Usta J, Szulc Z, Bielawska A, Obeid LM and Hannun YA . (2002). J. Biol. Chem., 277, 12960–12969.
Olivera A and Spiegel S . (1998). Methods Mol. Biol., 105, 233–242.
Olivera A, Edsall L, Poulton S, Kazlauskas A and Spiegel S . (1999a). FASEB J., 13, 1593–1600.
Olivera A, Kohama T, Edsall L, Nava V, Cuvillier O, Poulton S and Spiegel S . (1999b). J. Cell Biol., 147, 545–558.
Olivera A, Rosenfeldt HM, Bektas M, Wang F, Ishii I, Chun J, Milstien S and Spiegel S . (2003). J. Biol. Chem., 278, 46452–46460.
Osawa Y, Banno Y, Nagaki M, Brenner DA, Naiki T, Nozawa Y, Nakashima S and Moriwaki H . (2001). J. Immunol., 167, 173–180.
Perry DK and Hannun YA . (1998). Biochim. Biophys. Acta, 1436, 233–243.
Peter ME and Krammer PH . (2003). Cell Death Differ., 10, 26–35.
Pitson SM, Moretti PA, Zebol JR, Xia P, Gamble JR, Vadas MA, D'Andrea RJ and Wattenberg BW . (2000). J. Biol. Chem., 275, 33945–33950.
Raisova M, Bektas M, Wieder T, Daniel P, Eberle J, Orfanos CE and Geilen CC . (2000). FEBS Lett., 473, 27–32.
Raisova M, Goltz G, Bektas M, Bielawska A, Riebeling C, Hossini AM, Eberle J, Hannun YA, Orfanos CE and Geilen CC . (2002). FEBS Lett., 516, 47–52.
Raisova M, Hossini AM, Eberle J, Riebeling C, Wieder T, Sturm I, Daniel PT, Orfanos CE and Geilen CC . (2001). J. Invest. Dermatol., 117, 333–340.
Ricca A, Biroccio A, Del Bufalo D, Mackay AR, Santoni A and Cippitelli M . (2000). Int. J. Cancer, 86, 188–196.
Rius RA, Edsall LC and Spiegel S . (1997). FEBS Lett., 417, 173–176.
Satyamoorthy K, Bogenrieder T and Herlyn M . (2001). Trends Mol. Med., 7, 191–194.
Serrone L and Hersey P . (1999). Melanoma Res., 9, 51–58.
Shibasaki F, Kondo E, Akagi T and McKeon F . (1997). Nature, 386, 728–731.
Shu X, Wu W, Mosteller RD and Broek D . (2002). Mol. Cell. Biol., 22, 7758–7768.
Smalley KS . (2003). Int. J. Cancer, 104, 527–532.
Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R, Herman JG, Gerald WL, Lazebnik YA, Cordon-Cardo C and Lowe SW . (2001). Nature, 409, 207–211.
Strelow A, Bernardo K, Adam-Klages S, Linke T, Sandhoff K, Kronke M and Adam D . (2000). J. Exp. Med., 192, 601–612.
Taha TA, Osta W, Kozhaya L, Bielawski J, Johnson KR, Gillanders WE, Dbaibo GS, Hannun YA and Obeid LM . (2004). J. Biol. Chem., 279, 20546–20554.
Tang L, Tron VA, Reed JC, Mah KJ, Krajewska M, Li G, Zhou X, Ho VC and Trotter MJ . (1998). Clin. Cancer Res., 4, 1865–1871.
Thomas WD and Hersey P . (1998). J. Immunol., 161, 2195–2200.
Toman RE, Movsesyan V, Murthy SK, Milstien S, Spiegel S and Faden AI . (2002). J. Neurosci. Res., 68, 323–330.
Wieder T, Orfanos CE and Geilen CC . (1998). J. Biol. Chem., 273, 11025–11031.
Xia P, Wang L, Gamble JR and Vadas MA . (1999). J. Biol. Chem., 274, 34499–34505.
Yamamoto Y and Gaynor RB . (2001). Curr. Mol. Med., 1, 287–296.
Zhang J, Alter N, Reed JC, Borner C, Obeid LM and Hannun YA . (1996). Proc. Natl. Acad. Sci. USA, 93, 5325–5328.
Acknowledgements
Polyclonal anti-SphK1 antibody was a generous gift from Dr Murate and Dr Banno. MB was a recipient of a fellowship from the Free University of Berlin. This study was supported by grants from Deutsche Forschungsgemeinschaft (SFB 366 and Ge 641/5-2) to CCG and from the National Cancer Institute (R01CA61774) to SS. Cell sorting was supported in part by NIH Grant P30CA16059.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bektas, M., Jolly, P., Müller, C. et al. Sphingosine kinase activity counteracts ceramide-mediated cell death in human melanoma cells: role of Bcl-2 expression. Oncogene 24, 178–187 (2005). https://doi.org/10.1038/sj.onc.1208019
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208019
Keywords
This article is cited by
-
The Cross-Talk Between Sphingolipids and Insulin-Like Growth Factor Signaling: Significance for Aging and Neurodegeneration
Molecular Neurobiology (2019)
-
Sphingosine-1-Phosphate and Its Effect on Glucose Deprivation/Glucose Reload Stress: From Gene Expression to Neuronal Survival
Molecular Neurobiology (2015)
-
The pleiotropic roles of sphingolipid signaling in autophagy
Cell Death & Disease (2014)
-
Dual role of sphingosine kinase-1 in promoting the differentiation of dermal fibroblasts and the dissemination of melanoma cells
Oncogene (2014)
-
The use of a neutral peptide aptamer scaffold to anchor BH3 peptides constitutes a viable approach to studying their function
Cell Death & Disease (2014)